Denosumab for treatment of breast cancer bone metastases and beyond

Expert Opinion on Biological Therapy

Volumn 12, Issue 4, 2012, Pages 491-501

  Nangia, Julie R ^a   Ma, Joseph D ^b   Nguyen, Christine M ^c   Mendes, Margaret A S ^d   Trivedi, Meghana V ^e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Prescription Solutions   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF HOUSTON   (United States)

Author keywords

Bone metastasis; Breast cancer; Denosumab; RANK; RANKL

Indexed keywords

CLODRONIC ACID; DENOSUMAB; ETIDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ANEMIA; ARTHRALGIA; ASTHENIA; BACKACHE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CARCINOGENESIS; CONSTIPATION; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INFECTION; INJECTION SITE REACTION; JAW OSTEONECROSIS; KIDNEY FAILURE; MULTICENTER STUDY (TOPIC); NAUSEA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; RANK LIGAND;

EID: 84858683384     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.664634     Document Type: Review

References (92)

1. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6 (Pubitemid 17234155)
2. Lipton A, Uzzo R, Amato RJ, et al. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw 2009;7(Suppl 7):S1-29; quiz S30
3. Chen YC, Sosnoski DM, Mastro AM. Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res 2010;12:215
4. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998;19:18-54 (Pubitemid 29122073)
5. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005;10:169-80 (Pubitemid 41031006)
6. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64
7. Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer confined to the skeletal system. An indolent disease. Am J Med 1986;81:381-6 (Pubitemid 16003855)
8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. Version 2.2011. Available from: http://www.nccn.org/ professionals/ physician-gls/pdf/breast.pdf [Accessed on 1 April 2011]
9. Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011;29:1221-7
10. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007;119(Suppl 2):S150-62 (Pubitemid 46397937)
11. Kristensen B, Ejlertsen B, Groenvold M, et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999;246:67-74 (Pubitemid 29327354)
12. Paterson AH, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65 (Pubitemid 23059975)
13. Paterson AH, Powles TJ, Kanis JA, et al. Double-blind trial of oral clodronate in breast cancer patients with bone metastases. Bull Cancer 1993;80(10 Suppl):50-6
14. Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 2001;88:701-7 (Pubitemid 32831138)
15. Luhe A, Kunkele KP, Haiker M, et al. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. Toxicol In Vitro 2008;22:899-909
16. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038-44 (Pubitemid 28265038)
17. Hultborn R, Gundersen S, Ryden S, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999;19:3383-92 (Pubitemid 30000192)
18. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-54 (Pubitemid 29109314)
19. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21
20. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87 (Pubitemid 33759002)
21. Coleman RE. Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials. Am J Clin Oncol 2002;25(6 Suppl 1):S25-31 (Pubitemid 35453653)
22. Kanis JA, Powles T, Paterson AH, et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996;19:663-7 (Pubitemid 27035848)
23. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005(3):CD003474
24. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-21 (Pubitemid 38715767)
25. Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Suarez MA, Aguiar Morales J. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 2007;18:556-60 (Pubitemid 46359639)
26. Weide R, Koppler H, Antras L, et al. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review. J Cancer Res Ther 2010;6:31-5
27. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7 (Pubitemid 46211499)
28. Ito S, Wakabayashi K, Ubukata O, et al. Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. J Biol Chem 2002;277:6631-6 (Pubitemid 34968464)
29. Lam J, Nelson CA, Ross FP, et al. Crystal structure of the TRANCE/ RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest 2001;108:971-9 (Pubitemid 32946071)
30. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-9 (Pubitemid 27507987)
31. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76 (Pubitemid 28180851)
32. Wong BR, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in cells. J Biol Chem 1997;272:25190-4 (Pubitemid 27415705)
33. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-602
34. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008;473:139-46
35. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008;29:155-92 (Pubitemid 351519689)
36. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007;7:292-304 (Pubitemid 46480961)
37. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006;12:17-25 (Pubitemid 43089652)
38. Ikeda T, Kasai M, Utsuyama M, Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 2001;142:1419-26 (Pubitemid 32299669)
39. Hanada R, Hanada T, Penninger JM. Physiology and pathophysiology of the RANKL/RANK system. Biol Chem 2010;391:1365-70
40. Leibbrandt A, Penninger JM. RANK/ RANKL: regulators of immune responses and bone physiology. Ann NY Acad Sci 2008;1143:123-50
41. Fata JE, Kong YY, Li J, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000;103:41-50
42. Arron JR, Vologodskaia M, Wong BR, et al. A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (trance) and CD40L-mediated Akt activation. J Biol Chem 2001;276:30011-17
43. Bachmann MF, Wong BR, Josien R, et al. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 1999;189:1025-31 (Pubitemid 29169819)
44. Chen G, Sircar K, Aprikian A, et al. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006;107:289-98 (Pubitemid 44036558)
45. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006;440:692-6
46. Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234:137-42 (Pubitemid 27267548)
47. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/ OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-37 (Pubitemid 28510154)
48. Hill TP, Spater D, Taketo MM, et al. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 2005;8:727-38 (Pubitemid 40585295)
49. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19 (Pubitemid 27199902)
50. Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol 2011;6:121-45
51. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999;145:527-38 (Pubitemid 29215717)
52. Lacey DL, Tan HL, Lu J, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000;157:435-48 (Pubitemid 30626907)
53. Matsuzaki K, Udagawa N, Takahashi N, et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 1998;246:199-204 (Pubitemid 28413951)
54. O'Brien EA, Williams JH, Marshall MJ. Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. Biochem Biophys Res Commun 2000;274:281-90 (Pubitemid 30614312)
55. Schneeweis LA, Willard D, Milla ME. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. J Biol Chem 2005;280:41155-64 (Pubitemid 41832168)
56. Powell GJ, Southby J, Danks JA, et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 1991;51:3059-61
57. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999;140:4451-8 (Pubitemid 30666108)
58. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in thepathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-9 (Pubitemid 26327863)
59. Bendre MS, Montague DC, Peery T, et al. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 2003;33:28-37 (Pubitemid 36952685)
60. Wani MR, Fuller K, Kim NS, et al. Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. Endocrinology 1999;140:1927-35 (Pubitemid 29149267)
61. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44
62. Kang JS, Alliston T, Delston R, Derynck R. Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. EMBO J 2005;24:2543-55 (Pubitemid 41076311)
63. Xgeva. Prescribing Information. Thousand Oaks, CA. Amgen, Inc. 2010. Available from: http://www.xgeva.com [Last accessed 9 February 2012]
64. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled Phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431-7 (Pubitemid 350013849)
65. Yonemori K, Fujiwara Y, Minami H, et al. Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. Cancer Sci 2008;99:1237-42 (Pubitemid 351676637)
66. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1059-66 (Pubitemid 41110556)
67. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49:633-59
68. Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 2010;24:23-39
69. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69
70. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-8 (Pubitemid 43342512)
71. Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008; 14:6690-6
72. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-9
73. Fizazi K, Lipton A, Mariette X, et al. Randomized Phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-71
74. Amgen, Daiichi Sankyo, Inc. Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE). ClinicalTrial.gov NCT01077154 Available from: http://clinicaltrials.gov/ ct2/show/NCT01077154? term=NCT01077154&rank=1
75. Goss PE, Barrios CH, Bell R, et al. A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE). J Clin Oncol 2011;29(Suppl):abstract TPS152
76. Amgen. Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer. ClinicalTrial.gov NCT00286091 Available from: http://clinicaltrials.gov/ ct2/show/NCT00286091? term= NCT00286091&rank=1
77. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360:679-91
78. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008;34:453-75
79. Tanimori Y, Tsubaki M, Yamazoe Y, et al. Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits tumor metastasis in mouse melanoma through suppression of the Rho/ROCK pathway. Clin Exp Metastasis 2010; 27:529-38
80. Brisken C, Ayyannan A, Nguyen C, et al. IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Dev Cell 2002;3:877-87 (Pubitemid 35460787)
81. Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci USA 2003;100:9744-9 (Pubitemid 37087012)
82. Beleut M, Rajaram RD, Caikovski M, et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 2010;107:2989-94
83. Fernandez-Valdivia R, Mukherjee A, Ying Y, et al. The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev Biol 2009;328:127-39
84. Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferationand carcinogenesis. Nature 2010;468:103-7
85. Reinholz MM, Iturria SJ, Ingle JN, Roche PC. Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR. Breast Cancer Res Treat 2002; 74:255-69 (Pubitemid 34848353)
86. Van Poznak C, Cross SS, Saggese M, et al. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J Clin Pathol 2006; 59:56-63 (Pubitemid 43076239)
87. Santini D, Perrone G, Roato I, et al. Expression pattern of receptor activator of NFkappaB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol 2011;226:780-4
88. Santini D, Vincenzi B, Russo A, et al. Association of receptor activator of NF-kb (RANK) expression with bone metastasis in breast carcinomas. J Clin Oncol 2010;28:abstract 1053
89. Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010;468:98-102
90. Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011;470:548-53
91. Asselin-Labat ML, Vaillant F, Sheridan JM, et al. Control of mammary stem cell function by steroid hormone signalling. Nature 2010;465:798-802
92. Joshi PA, Jackson HW, Beristain AG, et al. Progesterone induces adult mammary stem cell expansion. Nature 2010;465:803-7